Delphinus Medical Technologies Appoints Dr. Rachel Brem to Its Board of Directors

NOVI, Mich.–(BUSINESS WIRE)–#SoftVueDelphinus Medical Technologies, Inc., the leader in advanced breast ultrasound technology, announced today that Rachel Brem, M.D, has joined the company’s board of directors, effective immediately. Dr. Brem is one of the nation’s most renowned radiologists and experts on breast imaging and intervention. She is currently the Director, Breast Imaging and Intervention at The George Washington University and the Program Leader, Breast Cancer, at The George Washington Cancer Center. She also serves as the Director of the Breast Imaging and Intervention Fellowship and Vice-Chair for Research and Faculty Development in the Department of Radiology at The George Washington University.


“We are thrilled to have Dr. Rachel Brem join our board of directors. Dr. Brem is an innovative leader in the field of breast cancer imaging and detection, a passionate patient advocate, and a pioneering radiologist who has helped to establish new imaging modalities and guidelines to detect breast cancer earlier in order to save lives,” said Delphinus Medical Technologies President and CEO, Mark Forchette. “Dr. Brem brings tremendous knowledge, vision and energy to Delphinus, and her insights to advancing clinical thought and practice will be invaluable as we move our SoftVue™ technology through the regulatory pathway. We are excited to have her expert counsel as we advance though clinical and regulatory targets in support of a supplemental screening indication for women with dense breasts in combination with mammography.”

Dr. Rachel Brem is founder of the Brem Foundation to Defeat Breast Cancer, an organization with the mission to maximize women’s chances of finding curable breast cancer through expert education, access to diagnostic tests, and physician training. Dr. Brem played a key role in the development of Computer Aided Design (CAD) and was involved in the first FDA cleared artificial intelligence product for mammography. In addition, she is actively involved in the advancement of Automated Breast Ultrasound Systems (ABUS), Molecular Breast Imaging (MBI) and Magnetic Resonance Imaging (MRI) as supplemental breast imaging modalities.

Dr. Brem earned her medical degree from Columbia University. She completed her internship in internal medicine at the Sinai Hospital of Baltimore and her residency in radiology at the Johns Hopkins Hospital. She pursued further training in magnetic resonance imaging and breast imaging as a fellow at Johns Hopkins Medical institutions.

About Delphinus Medical Technologies, Inc.

Headquartered in Novi, Mich., Delphinus Medical Technologies, Inc. is a pioneering medical imaging company that has developed SoftVue, featuring the first circular array transducer technology that has received sequential U.S. Food and Drug Administration clearances. The patented technology is a 3D whole breast ultrasound imaging device that delivers no radiation, requires no compression, and images the entire breast with a single scan. SoftVue is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography. Delphinus was founded as a spin out of the Karmanos Cancer Institute in Detroit and is capitalized through principal investments by Arboretum Ventures, Ann Arbor, Mich., Beringea, Farmington Hills, Mich., North Coast Technology Investors, Ann Arbor, Mich., Venture Investors, Madison, Wis., Hopen Life Science Ventures, Grand Rapids, Mich., and Waycross Ventures, Menlo Park, Calif. For more information, visit www.delphinusmt.com.

* SoftVue™ is indicated for use as a B-mode ultrasonic imaging system and is not intended to be used as a replacement for screening mammography.

Contacts

Diana Soltesz

Nobles Global Communications

Email: diana@noblesgc.com

Office: 818-618-5634

Author: dmnnewswire